(RTTNews) - PTC Therapeutics, Inc. (PTCT), a biopharmaceutical company, said Tuesday that its Board of Directors has authorized a share repurchase program of up to $500 million.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.